Cargando…
Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619155/ https://www.ncbi.nlm.nih.gov/pubmed/34835130 http://dx.doi.org/10.3390/v13112324 |
_version_ | 1784604921733054464 |
---|---|
author | Vollenberg, Richard Tepasse, Phil-Robin Ochs, Kevin Floer, Martin Strauss, Markus Rennebaum, Florian Kabar, Iyad Rovas, Alexandros Nowacki, Tobias |
author_facet | Vollenberg, Richard Tepasse, Phil-Robin Ochs, Kevin Floer, Martin Strauss, Markus Rennebaum, Florian Kabar, Iyad Rovas, Alexandros Nowacki, Tobias |
author_sort | Vollenberg, Richard |
collection | PubMed |
description | The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter for measuring glycocalyx injury. This prospective, multicenter, observational, cross-sectional study analyzed SDC-1 levels in 24 convalescent patients that had been infected with SARS-CoV-2 with mild disease course without need of hospitalization. We included 13 age-matched healthy individuals and 10 age-matched hospitalized COVID-19 patients with acute mild disease course as controls. In convalescent COVID-19 patients, significantly elevated SDC-1 levels were detected after a median of 88 days after symptom onset compared to healthy controls, whereas no difference was found when compared to SDC-1 levels of hospitalized patients undergoing acute disease. This study is the first to demonstrate signs of endothelial damage in non-pre-diseased, convalescent COVID-19 patients after mild disease progression without hospitalization. The data are consistent with studies showing evidence of persistent endothelial damage after severe or critical disease progression. Further work to investigate endothelial damage in convalescent COVID-19 patients should follow. |
format | Online Article Text |
id | pubmed-8619155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86191552021-11-27 Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis Vollenberg, Richard Tepasse, Phil-Robin Ochs, Kevin Floer, Martin Strauss, Markus Rennebaum, Florian Kabar, Iyad Rovas, Alexandros Nowacki, Tobias Viruses Article The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter for measuring glycocalyx injury. This prospective, multicenter, observational, cross-sectional study analyzed SDC-1 levels in 24 convalescent patients that had been infected with SARS-CoV-2 with mild disease course without need of hospitalization. We included 13 age-matched healthy individuals and 10 age-matched hospitalized COVID-19 patients with acute mild disease course as controls. In convalescent COVID-19 patients, significantly elevated SDC-1 levels were detected after a median of 88 days after symptom onset compared to healthy controls, whereas no difference was found when compared to SDC-1 levels of hospitalized patients undergoing acute disease. This study is the first to demonstrate signs of endothelial damage in non-pre-diseased, convalescent COVID-19 patients after mild disease progression without hospitalization. The data are consistent with studies showing evidence of persistent endothelial damage after severe or critical disease progression. Further work to investigate endothelial damage in convalescent COVID-19 patients should follow. MDPI 2021-11-21 /pmc/articles/PMC8619155/ /pubmed/34835130 http://dx.doi.org/10.3390/v13112324 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Vollenberg, Richard Tepasse, Phil-Robin Ochs, Kevin Floer, Martin Strauss, Markus Rennebaum, Florian Kabar, Iyad Rovas, Alexandros Nowacki, Tobias Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis |
title | Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis |
title_full | Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis |
title_fullStr | Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis |
title_full_unstemmed | Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis |
title_short | Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis |
title_sort | indications of persistent glycocalyx damage in convalescent covid-19 patients: a prospective multicenter study and hypothesis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619155/ https://www.ncbi.nlm.nih.gov/pubmed/34835130 http://dx.doi.org/10.3390/v13112324 |
work_keys_str_mv | AT vollenbergrichard indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT tepassephilrobin indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT ochskevin indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT floermartin indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT straussmarkus indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT rennebaumflorian indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT kabariyad indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT rovasalexandros indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis AT nowackitobias indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis |